PASG 8-K: Passage BIO, Inc. Announces Results of 2026 Annual Meeting of Stockholders
Key Points:
- Passage BIO, Inc. (NASDAQ: PASG) held its 2026 Annual Meeting of Stockholders on May 19, 2026.
- The meeting included votes on several critical proposals, including the election of directors, ratification of the auditor, and advisory votes on executive compensation and its frequency.
- All proposals were adopted, with detailed results for each item provided below.
Details of the Annual Meeting Results:
1. Election of Directors
The Company held elections for its board of directors. Shareholders voted through proxy to elect directors, though specific names and vote counts are not provided in this document. This typically ensures continuity in leadership and strategic direction.
2. Ratification of Auditor
Proposal: Ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
Results:
- Shares For: 2,083,031
- Shares Against: Not specified
- Shares Abstaining: Not specified
- Broker Non-Votes: Not specified
This ratification secures the integrity and transparency of PASG’s financial reporting, which is critical for investor confidence.
3. Advisory Vote on Executive Compensation
Proposal: Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers as disclosed in the proxy statement.
Results:
- Shares For: 1,452,505
- Shares Against: 36,352
- Shares Abstaining: 1,356
- Broker Non-Votes: 637,397
The majority approval of executive compensation reflects shareholder support for current leadership and compensation practices, which is often seen as a sign of stability and trust in management.
4. Advisory Vote on Frequency of Executive Compensation Vote
Proposal: Shareholders were asked to advise on the frequency of holding future advisory votes on executive compensation (every one, two, or three years).
Results:
- Shares for One Year: 1,450,605
- Shares for Two Years: 6,419
- Shares for Three Years: 637,397
- Abstaining: Not specified
- Broker Non-Votes: Not specified
Outcome: The Company’s stockholders advised favoring an annual (every year) frequency for future advisory votes on executive compensation. The board has adopted this policy, which will remain until the next required shareholder vote on frequency.
This decision increases shareholder engagement and aligns corporate governance practices with investor preferences.
Other Notable Disclosures
- Passage BIO, Inc. is not an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Exchange Act of 1934. This classification may affect the company’s regulatory and reporting requirements.
- There were no written communications, soliciting materials, or pre-commencement tender offers associated with this filing, indicating no extraordinary corporate actions or takeover activity at this time.
- The only security registered is Common Stock, \$0.0001 par value per share, traded under the symbol PASG on the NASDAQ Stock Market LLC (Nasdaq Capital Market).
- The report was signed by Kathleen Borthwick, Chief Financial Officer, on May 26, 2026.
Potential Impact for Investors:
- The ratification of KPMG LLP as auditor and approval of executive compensation are positive signals for shareholders, indicating continuity and stability in governance and financial reporting practices.
- The decision to hold annual advisory votes on executive compensation may be seen as enhancing shareholder rights and transparency, which could be viewed positively by institutional investors.
- No significant corporate actions or changes were disclosed that would immediately affect share value.
Conclusion:
The 2026 Annual Meeting of Passage BIO, Inc. was marked by the adoption of all proposals, reflecting strong shareholder support for the company’s management, compensation practices, and auditor selection. The move to annual advisory votes on executive compensation demonstrates a commitment to shareholder engagement. While there are no extraordinary or price-sensitive disclosures in this filing, the overall results may reinforce investor confidence and are consistent with sound corporate governance.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should perform their own due diligence and consult with professional advisors before making investment decisions. The information is based on the official SEC filing and may be subject to change or further updates.
